Phase 1 Study of ANAVEX3-71

Healthy Clinical Trial

Official title:

A Double-blind, Randomized, Placebo-controlled, Phase 1 Safety and Tolerability, and Pharmacokinetics Study of ANAVEX3-71

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04442945
• Other study ID #: ANAVEX3-71-001
• Status: Completed
• Phase: Phase 1
• Start date: July 3, 2020
• Est. completion date: October 30, 2021

Study information

• Verified date: January 2022
• Source: Anavex Life Sciences Corp.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A first in human phase 1 study in healthy volunteers to assess ANAVEX3-71 safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics

Description:

This is a first-in-human Phase 1 study designed to investigate the safety, tolerability, PK, PD and bioavailability of orally administered ANAVEX3-71 in healthy volunteers

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: October 30, 2021
• Est. primary completion date: September 30, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Healthy, male or female between 18 and 55 years of age, inclusive.

• Body mass index (BMI) between 19-28 kg/m2 and within a body weight of = 60 kg and = 120 kg.

• Female subjects must be of non-childbearing potential (defined as postmenopausal for at least 2 years or surgically sterile at least 6 months prior to dosing) or must be using adequate contraception.

• Subject is judged by the investigator to be in generally good health at screening based upon the results of a medical history, physical examination, laboratory profile, and 12-lead electrocardiogram (ECG).

• Non-smoker (no tobacco use within past 3 months).

• Subject is willing to comply with the study protocol, in the investigator's judgement.

Exclusion Criteria:

• Subject has a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, dermatological, neurological, psychiatric, hematological (including myelosuppression and bleeding disorders) or immunological/autoimmune disorder(s), and/or any condition that could constitute a potential safety risk factor or could alter the absorption, distribution, metabolism or elimination of the study drugs.

• Positive test result on Hepatitis B surface antigen (HBsAg) or is Hepatitis C virus antibody (HCV-Ab) positive or positive HIV-1 and/or -2 serology.

• Subject has a history of chronic alcohol abuse within the last 2 years, or has a positive alcohol test or is known to have excessive alcohol intake.

• History of substance abuse, known drug addiction, or positive test for drugs of abuse.

• Subject has participated in another clinical trial of an investigational drug (or a medical device) within the last 3 months or is currently participating in another trial of an investigational drug (or a medical device).

• Female subject who is pregnant or lactating or planning a pregnancy.

• A history of major mental illness that in the opinion of the Investigator may affect the ability of the subject to participate in the study (psychosis is to be disqualified).

• Subject has a condition the Investigator believes would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the subject at undue risk.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• ANAVEX3-71
Active oral dose of ANAVEX3-71
• Placebo
Oral placebo

Locations

Country	Name	City	State
Australia	CMAX Clinical Research Pty Ltd	Adelaide	South Australia

Sponsors (2)

Lead Sponsor	Collaborator
Anavex Life Sciences Corp.	Anavex Australia Pty Ltd.

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of safety and tolerability of ANAVEX3-71 measured by number of subjects with adverse events and Dose Limiting Adverse Event (DLAEs) Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	Incidence of adverse events and dose limiting Adverse Events during the DLAE observation period and/or study treatment periods.	30 days
Primary	Pharmacokinetics (PK) of ANAVEX3-71	Serum concentration of ANAVEX3-71 at specified time points	30 days
Primary	Maximum plasma concentration (Cmax) for ANAVEX3-71	Evaluate Cmax for serum concentration of ANAVEX3-71 at specified time points	30 days
Primary	Area under the curve concentration (AUC) for ANAVEX3-71	Evaluate AUC for serum concentration of ANAVEX3-71 at specified time points	30 days
Secondary	Effect on ECG, including the ECG QT Interval	To characterize the effect on ECG, including the ECG QT Interval for ANAVEX3-71	30 days